by Sunshine Biopharma | May 22, 2022 | Sec Filings
Filed pursuant to Rule 424(b)(3)Under the Securities Act of 1933, as amendedRegistration No. 333-264830 Pursuant to this prospectus, the selling stockholders identified herein are offering on a resale basis an aggregate of 14,588,535 shares of common stock, par value...
by Sunshine Biopharma | Apr 28, 2022 | News
MONTREAL, April 28, 2022 (GLOBE NEWSWIRE) — Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today...
by Sunshine Biopharma | Apr 25, 2022 | News
Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that two of its newly designed...
by Sunshine Biopharma | Apr 5, 2022 | News
A Potential Multi-Billion Dollar Global Market Opportunity for Cancer Treatments Montreal, Quebec, Canada – (GLOBE NEWSWIRE) – Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”), a pharmaceutical company focused on the research, development and commercialization of...
